ALTASCIENCES/VIRPAX
Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film.
The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada. “We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony P. Mack.
Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels.
Altasciences leverages decades of experience conducting first-in-human clinical trials, a vast database of study participants, and state-of-the-art bioanalytical facilities to provide expert guidance and personalized solutions. Ingrid Holmes, Altasciences’ Vice President, Global Clinical Operations, says, “We are proud to partner with Virpax to help move this important therapeutic further along the path to regulatory approval.”
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single service or a synchronized approach to CRO and CDMO services, from lead candidate selection to clinical proof of concept, and beyond.
More information on Virpax® Pharmaceuticals, Inc.’s program can be found here .
You may also be interested in:
Altasciences Chosen by Respira Technologies, Inc as Drug Product Manufacturing Partner
Altasciences Chosen by XORTX Therapeutics, Inc. to Conduct Pharmacokinetic Bridging Study
Other exciting news
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005256/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect29.5.2025 08:13:00 CEST | Press release
CE-marked under the EU IVDR regulation, Diagnostics.ai's platform is the first to deliver algorithmic transparency and per-test auditability for clinical PCR diagnostics Revolutionary Platform Sets New Benchmark for Transparency and Compliance in Diagnostic AI As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry’s first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning. The technology is backed by over 15 years of experience and millions of successfully processed samples with >99.9% proven accuracy. The CE-IVDR Strategic Advantage Platform is Diagnostics.ai's response to the new wave of stringent EU regulations under the In Vitro Diagnostic Medical Devices Regulation (IVDR), which demand heightened standards for diagnostic accuracy, reproducibility, and algorithm transparency. “While most diagnostic algorith
From Ancient Grounds to an Intelligent Future: The 1st International Humanoid Olympiad Launches in Olympia, Greece29.5.2025 00:47:00 CEST | Press release
This year, Olympia, Greece, the birthplace of the Olympic Games, welcomes the inaugural International Humanoid Olympiad. From August 29th to September 2nd, at the International Olympic Academy in Olympia, humanoid robots will participate in demonstrations and Olympic-inspired games, showcasing their dexterity and intelligence, while global leaders in robotics and AI will share insights through expert talks and workshops. Blending millennia-old values, ethos, and ideals with a bold vision for the future, the event will spotlight how human creativity and robotics are shaping the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528788233/en/ This global gathering brings together state-of-the-art humanoid robots in spectacular showcases designed to captivate audiences of all ages and backgrounds while their creators, researchers, engineers, students, and visionaries are pushing the boundaries of what intelligent machine
Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair28.5.2025 22:29:00 CEST | Press release
Mary Kay Inc., a global advocate for furthering young women’s education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainable packaging innovation and protecting our planet’s most valuable resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528325390/en/ Kristin Dasaro, Director, Package Engineering and Sustainability at Mary Kay, greets Brazilian cancer researcher, Carolina de Araujo Pereira da Silva, who received back-to-back awards from Mary Kay for innovative findings in the malignancy of tumors. (Photo Credit: Mary Kay Inc.) Each year, the event convenes nearly 2,000
Duravant Completes Acquisition of Pattyn28.5.2025 19:44:00 CEST | Press release
Automation Equipment Leader Duravant expands Packaging Group with Acquisition of Pattyn Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the protein processing, food sorting and handling, packaging, and material handling sectors, announced the completion of its acquisition of the Pattyn Group BV (“Pattyn”), a leading manufacturer of packaging automation systems headquartered in Bruges, Belgium. The transaction was first announced on February 7, 2025, and was completed today. With over 70 years of expertise, Pattyn is a trusted partner for companies looking to automate bulk packaging operations in industries ranging from food and ingredients to non-food applications. Pattyn has been a world-renowned brand specializing in bag-in-box packaging technology, and their comprehensive end-of-line solutions span the entire packaging process from case erecting and bag inserting to weigh filling, bag and case closing, and palletizing. “We are extremely
Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer28.5.2025 18:00:00 CEST | Press release
Seasoned business and IT executive leader to drive operational efficiency, scaling, increased profitability and accelerated growth of the business Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Vijay Kumar as executive vice president (EVP) and chief operating officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528704180/en/ Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer In this role, Mr. Kumar leads product management, service strategy and offerings for Rimini Street’s “Support, Optimize and Innovate” solutions and oversees Rimini Street’s Global Capability Centers (GCC). Mr. Kumar also drives operational efficiency and innovation of the portfolio to increase profitability and accelerate t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom